Nanoengineered patches and injectables aim to fight cancer locally
NCT ID NCT05893888
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests three new ways to deliver the chemotherapy drug cisplatin directly to tumors in the mouth or lungs. The goal is to kill cancer cells while reducing side effects on the rest of the body. About 40 adults with early-stage oral or lung cancer will receive the treatment as a patch, a surgical implant, or an injection. The trial is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cisplatin (delivered via PRV111 patch, PRV211 intraoperative system, or PRV131 injectable)
What this could lead to
If successful, this could offer a more targeted, less toxic way to deliver chemotherapy directly to tumors, potentially improving outcomes for oral and lung cancers.
What could go wrong
This is an early-phase trial with only 40 participants, so results may not apply broadly. The treatments involve cisplatin, which can cause side effects like kidney damage and nerve issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ORAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope National Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Miami Cancer Institute
RECRUITINGMiami, Florida, 33176, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Cleveland Clinic Foundation
RECRUITINGCleveland, Ohio, 44195, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The University of Chicago
RECRUITINGChicago, Illinois, 60637, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••